NEP Continues To Expand NEPTune Platform Offerings

Enhanced Services Designed To Meet Needs of Growing Proteomics Market


GARDNER, Mass – New England Peptide, LLC (NEP) has responded to the expanding needs of the field of proteomics by offering expanded custom isotope labeling and post translational modification options to customers through its innovative NEPTuneTM product line.


The use of isotopically labeled peptides for proteomics assays has traditionally included 13C, 15N isotopically labeled C terminal lysine and arginine. In addition to biomarker identification these labeled peptides are also used to analyze the vast number of potential PTMs that occur in a proteome, such as phosphorylation.


In response to new market needs, NEP now offers a variety of additional labels including deuterated amino acids, selective 15N and 13C labeling, and the flexibility to label positions alternative to the C terminus. This provides researchers with more options to develop custom assays. Additionally NEP is now able to guarantee >99% isotopic purity for universally labeled lysine and arginine ensuring the best possible quantitation in Multiple Reaction Monitoring (MRM).


“New focuses in proteomics, including an emphasis on post translational modifications, have increased demand for a wider variety of labels and other modifications,” said Robert Hammer, NEP’s Vice President of Chemistry. “Expanding the NEPTuneTM line provides our customers with a host of PTMs - such as nitrosylation, chlorination, glycosylation, and methylation - increasing synthetic access to interesting protein behavior.”


NEPTune’s growing platform of custom proteomics reagents and related services is the only product line designed to serve as the enabling platform for biomarker assay development and the global initiative to map the proteomes of all species.


NEPTuneTM comprises a suite of four distinct solutions that align with the various needs of proteomics researchers and clinicians, ranging from biomarker discovery through clinical assay production. Each NEPTuneTM solution delivers end product, supporting analysis and sample preparation in an MRM-ready format.


“New England Peptide continues to forge its position as a market leader in the field of proteomics due to our commitment to the NEPTuneTM product line,” said NEP CEO Dave Robinson. “Since launching NEPTuneTM last summer we have continually worked to standardize our offerings and facilitate collaboration throughout the industry.”


Customers interested in the industry’s newest set of proteomics services should contact NEP’s business development group at 888-343-5974.


AboutNew EnglandPeptide - NEP


NEP, founded in 1998, designs and produces custom peptides and polyclonal antibodies for drug and vaccine discovery organizations worldwide. Headquartered in theBostonmetro area inGardner,Mass., the company’s chemists and immunological experts specialize in delivering a full range of services for biotech and pharmaceutical applications.


Peptides are smaller segments of proteins or short polymers of amino acids that play key roles in biochemical regulation of all life systems, helping to fight diseases as diverse as cancer, diabetes, obesity and HIV/AIDS. Peptides’ inherent low toxicity and high potency, coupled with improved drug delivery methods and enhanced manufacturing capabilities, are fueling a surge in research and clinical use.




"THANKS AGAIN for all the intellectual support that NEP has provided to us over the last year. My colleagues have been overwhelmingly impressed with the quality of service and level of thought that you have put into researching and thinking about our particular peptide and antibody production needs. The level of scholarship went well beyond what we expected from any peptide and antibody company, and was crucial in shaping our decisions. It has truly been a pleasure corresponding with you."
Cliff N. PhD - Lawrence Berkeley National Laboratory